Reducing Lentiviral Vector Manufacturing Timelines with dbDNA™
Lentiviral vectors are essential for some of today’s most transformative cell and gene therapies, from CAR-T to modified stem cell treatments. But making them efficiently and at scale is still a challenge. Traditional plasmid DNA (pDNA) manufacturing is slow, labour-intensive, and prone to batch variability, hurdles that slow timelines and increase costs.
dbDNA™ offers a better alternative
As a linear, enzymatically amplified DNA construct, dbDNA is produced without bacterial fermentation, eliminating antibiotic resistance sequences and bacterial-derived impurities. The result? Highly pure DNA, ready for research or GMP manufacturing, with a faster, scalable process without the use of animal derived components.
Proven performance across lentiviral vectors generations
In collaboration with Expression Manufacturing, Touchlight’s dbDNA was compared with pDNA in both 2.5th- and 3rd-generation lentiviral vectors systems. The findings were clear:
- Comparable infectious titres to pDNA when delivering a GFP transgene
- Up to 40% greater infectious titres for a clinical-stage ET3 transgene using dbDNA
- Consistent performance across vector system generations
Why it matters
Switching to dbDNA reduces production time, enhances batch consistency, and removes unwanted impurities, paving the way for more efficient lentiviral vectors manufacturing, and accelerating the path from development to clinic. Touchlight’s cell-free DNA platform is already helping clients bring innovative therapies to patients faster.
Read the full application note to explore how dbDNA™ can optimise your LVV production.
